Taysha Gene Therapies, Inc. (TSHA)
Drugs • Health Care
August 03, 2026 Taysha Gene Therapies Expands Strategic Partnership with Catalent for TSHA-102 Manufacturing Taysha Gene Therapies has announced an expanded partnership with Catalent for the commercial manufacturing of TSHA-102, a gene therapy for Rett syndrome. This agreement secures long-term manufacturing capacity and positions Taysha for a successful launch of the therapy, which targets the root cause of this rare condition affecting thousands of patients.
June 25, 2026 Taysha Gene Therapies Announces Public Offering of Common Stock Taysha Gene Therapies has announced a public offering of 32.5 million shares at $6 each, aiming to raise $200 million for its gene therapy research. This move reflects confidence in the company's innovative approach to treating severe CNS disorders, with a focus on the lead candidate TSHA-102 for Rett syndrome.
June 25, 2026 Taysha Gene Therapies Showcases TSHA-102 Clinical Advancements at IRSF Meeting Taysha Gene Therapies is set to present pivotal data on its TSHA-102 gene therapy for Rett syndrome at the 2026 IRSF meeting. With oral and poster presentations, the company aims to highlight the safety, efficacy, and innovative design of this groundbreaking therapy addressing critical unmet needs in treating Rett syndrome.
June 24, 2026 Taysha Gene Therapies Announces Major Public Offering Taysha Gene Therapies is moving forward with a $200 million public offering aimed at enhancing its financial resources to develop gene therapies for severe central nervous system disorders. This strategic initiative includes a focus on TSHA-102, targeting Rett syndrome, and is backed by prominent financial institutions, highlighting the company's commitment to innovation in biotechnology.
June 22, 2026 Taysha Gene Therapies Reports Positive Milestones in TSHA-102 Development for Rett Syndrome Taysha Gene Therapies has successfully completed dosing in the REVEAL trial for TSHA-102, showing early treatment effects for Rett syndrome. With 100% of participants regaining developmental milestones, the company is preparing for a potential BLA submission while continuing to evaluate safety and efficacy in younger patients.
June 05, 2026 Taysha Gene Therapies Expands Team with Inducement Grant Under Nasdaq Rule Taysha Gene Therapies has granted inducement equity awards to four new employees, including RSUs and stock options, to boost its talent pool. This strategic move underscores the company's commitment to advancing its gene therapy programs while complying with Nasdaq regulations.
May 06, 2026 Taysha Gene Therapies Reports Strong Progress Amid First Quarter 2026 Financial Results Taysha Gene Therapies showcases significant advancements in its TSHA-102 program for Rett syndrome following its Q1 2026 financial results. The company aligns with the FDA for a BLA submission and reports positive safety data, despite increased R&D expenses.
May 01, 2026 Taysha Gene Therapies Grants Restricted Stock Units to New Employees Taysha Gene Therapies has announced the grant of 188,000 restricted stock units to new employees to attract top talent for its innovative gene therapy programs. This strategic move aligns employee interests with company success, fostering a culture of innovation in treating severe CNS diseases.
April 29, 2026 Taysha Gene Therapies Set to Announce First Quarter 2026 Financial Results Taysha Gene Therapies is set to announce its first quarter 2026 financial results on May 6, focusing on advancements in gene therapies for CNS diseases. The conference call will provide updates on their clinical programs and financial health, highlighting their commitment to addressing severe monogenic diseases.
April 27, 2026 Taysha Gene Therapies Unveils Promising Data for TSHA-102 in Rett Syndrome Taysha Gene Therapies announced significant preclinical findings for TSHA-102, a gene therapy targeting Rett syndrome. The data show enhanced efficacy in neuronal models, supporting the therapy's potential as a breakthrough treatment for this rare disorder.
April 03, 2026 Taysha Gene Therapies Grants Inducement Stock Options and RSUs to New Employees Taysha Gene Therapies announces an inducement grant of stock options and RSUs to attract four new employees. This strategic move aims to strengthen its workforce as the company develops innovative gene therapies for severe CNS diseases.
March 19, 2026 Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Corporate Update Taysha Gene Therapies reports a net loss of $109 million for 2025 while advancing its lead product, TSHA-102, in pivotal trials for Rett syndrome. The company anticipates significant developments in 2026, including FDA engagement and trial completion.
March 19, 2026 Taysha Gene Therapies, Inc. Reports 2025 Annual Results: Progress Amidst Financial Challenges Taysha Gene Therapies, focused on AAV-based gene therapies, reports promising clinical results for TSHA-102 in treating Rett syndrome, despite facing significant financial losses. The company plans to continue advancing its clinical trials while seeking additional capital for sustainability.
March 12, 2026 Taysha Gene Therapies Set to Release Full-Year 2025 Financial Results Taysha Gene Therapies is set to release its full-year 2025 financial results on March 19, 2026. The conference call will provide valuable insights into the company’s financial health and clinical advancements, particularly regarding their lead program for Rett syndrome.
March 06, 2026 Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Taysha Gene Therapies has approved an inducement grant for a new employee, comprising 156,870 RSUs and stock options. This move highlights the company's dedication to attracting top talent as it develops gene therapies for severe CNS disorders.
February 06, 2026 Taysha Gene Therapies Grants Inducement Stock Awards to New Employees Taysha Gene Therapies has granted 349,000 RSUs to three new employees to strengthen its workforce and advance its mission in gene therapy for severe CNS diseases. This strategic move aligns with the company's growth initiatives and expertise in biotechnology.
January 06, 2026 Taysha Gene Therapies Reports Significant Advancements in TSHA-102 Pivotal Gene Therapy Program for Rett Syndrome Taysha Gene Therapies has made significant strides in its TSHA-102 gene therapy program targeting Rett syndrome, including patient dosing in pivotal trials and FDA alignment. This innovative therapy aims to modify the disease's course and has the potential to transform treatment options for thousands affected by Rett syndrome.
December 05, 2025 Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Taysha Gene Therapies has granted stock options to new employees as part of its inducement plan, aimed at attracting talent in the competitive biotech sector. The options are tied to the company's mission of developing innovative gene therapies for CNS disorders, including Rett syndrome.
November 04, 2025 Taysha Gene Therapies Reports Strong Third Quarter 2025 Results and Major Regulatory Advancements Taysha Gene Therapies reported promising Q3 2025 results, including FDA Breakthrough Therapy designation for TSHA-102 focused on Rett syndrome. Their pivotal REVEAL trial protocol is finalized, showing a 33% response rate in early trials. The company is well-positioned for future growth with significant financial backing and strategic advancements.
November 04, 2025 Taysha Gene Therapies, Inc. Reports Q3 2025 Results: Focus on Advancing Gene Therapy for Rett Syndrome Taysha Gene Therapies announced its Q3 2025 results, highlighting advancements in TSHA-102 for Rett syndrome and a net loss of $32.73 million. The company remains focused on clinical trials while managing financial resources effectively.
October 28, 2025 Taysha Gene Therapies Set to Release Q3 2025 Financial Results Taysha Gene Therapies plans to release its Q3 2025 financial results on November 4, 2025, during a conference call. The company focuses on developing innovative gene therapies for severe CNS disorders, emphasizing its commitment to transformative medicines.
October 16, 2025 Taysha Gene Therapies Regains Control of TSHA-102 Program for Rett Syndrome Taysha Gene Therapies has regained control of its TSHA-102 program for Rett syndrome following the expiration of its agreement with Astellas. With promising clinical data showing a 100% response rate on key endpoints, Taysha is well-positioned to advance toward late-stage development and commercialization.
October 09, 2025 Taysha Gene Therapies Reports Promising Data for TSHA-102 in Rett Syndrome Taysha Gene Therapies announced positive results from the REVEAL trials for TSHA-102, a gene therapy for Rett syndrome, highlighting significant developmental milestones and functional gains in patients. This innovative treatment aims to address the genetic cause of the disorder, offering hope for improved quality of life.
October 03, 2025 Taysha Gene Therapies Grants Stock Options to New Employees: A Strategic Move Under Nasdaq Rules Taysha Gene Therapies has granted stock options to new employees as part of a strategic move to attract top talent. This initiative, compliant with Nasdaq rules, aims to align employee interests with shareholders while enhancing the company's workforce in gene therapy development.
October 02, 2025 Taysha Gene Therapies Achieves Major Regulatory Milestone with TSHA-102 for Rett Syndrome Taysha Gene Therapies has received FDA Breakthrough Therapy designation for TSHA-102, an AAV9 gene therapy for Rett syndrome, showing a 100% response rate in early trials. This milestone accelerates the path to potential FDA approval and addresses a significant unmet need for patients.
August 12, 2025 Taysha Gene Therapies, Inc. Reports Q2 2025 Financial Results: A Steady Path Towards Innovation in Gene Therapy Taysha Gene Therapies reported its Q2 2025 financial results, highlighting progress in clinical trials for TSHA-102 aimed at treating Rett syndrome. Despite increased operating losses, the company remains committed to innovation in gene therapy and has strengthened its financial position through successful funding efforts.
May 15, 2025 Taysha Gene Therapies, Inc. Q1 2025 Financial Report: Navigating Challenges in Gene Therapy Development Taysha Gene Therapies reported its Q1 2025 financial results, showcasing clinical advancements with TSHA-102 while addressing ongoing financial challenges, including a net loss reduction. The company anticipates sharing more data from its trials focused on treating Rett syndrome in the coming months.
March 13, 2025 SWOT Analysis of Taysha Gene Therapies, Inc. in 2025 This SWOT analysis of Taysha Gene Therapies, Inc. reviews its strengths like innovative gene therapies and regulatory advantages, while addressing weaknesses such as financial losses. It also explores opportunities for growth and the threats posed by competition and regulatory changes as the company strives for success in the biotechnology landscape.
March 07, 2025 Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan Taysha Gene Therapies has granted stock options to three new employees as part of its strategy to attract top talent. The options, totaling 225,000 shares, align with the company's mission to innovate in gene therapy for severe neurological diseases.
February 26, 2025 Taysha Gene Therapies, Inc. Reports 2024 Annual Results Amidst Clinical Advancements and Financial Challenges Taysha Gene Therapies, Inc. reports its 2024 annual results, highlighting advancements in clinical trials for TSHA-102 aimed at treating Rett syndrome, despite facing financial losses. The company remains focused on its strategic collaborations and regulatory milestones while navigating ongoing legal proceedings.
February 26, 2025 Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Corporate Update Taysha Gene Therapies has released its 2024 financial results, showcasing progress in its TSHA-102 clinical trials for Rett syndrome. The company is engaged in ongoing FDA discussions and has a strong cash position to support future developments.
February 19, 2025 Taysha Gene Therapies Set to Reveal 2024 Financial Results: Conference Call Scheduled for February 26 Taysha Gene Therapies, a leader in gene therapies for CNS diseases, will announce its 2024 financial results on February 26, 2025. The conference call will provide valuable insights into its progress and strategic direction, particularly in addressing severe neurological disorders like Rett syndrome.
February 07, 2025 Taysha Gene Therapies Grants Inducement Stock Options as Part of Nasdaq Compliance Taysha Gene Therapies has granted 491,000 stock options to three new employees to comply with Nasdaq regulations. This move is part of their strategy to attract talent while advancing their gene therapy programs, particularly for treating Rett syndrome.
November 13, 2024 Taysha Gene Therapies, Inc. Reports Q3 2024 Financial Results: Progress Amidst Losses Taysha Gene Therapies, Inc. reports a net loss of $25.52 million in Q3 2024, yet highlights improvements in financial management and ongoing clinical trials, particularly for its lead candidate TSHA-102 for Rett syndrome. The company is focusing on strategic collaborations and refining its pipeline amidst challenging financial conditions.
August 12, 2024 Taysha Gene Therapies Reports Promising Developments in Q2 2024 Financial Results Taysha Gene Therapies reported significant developments in its Q2 2024 financial results, focusing on its lead candidate TSHA-102 for Rett syndrome. The company achieved positive outcomes in ongoing clinical trials and maintains a strong financial foundation, emphasizing operational efficiency and future growth.
May 14, 2024 Taysha Gene Therapies, Inc.: Q1 2024 Financial Report Analysis Taysha Gene Therapies, Inc. reported a net loss of $24.1 million for Q1 2024, reflecting increased R&D investments. The company is advancing its lead gene therapy, TSHA-102, for Rett syndrome while strategically deprioritizing other programs. Their financial performance indicates a focus on clinical development and funding for future growth.